Developing novel therapeutics to treat rare, cholestatic liver diseases
Mirum Pharmaceuticals is developing a novel approach for treating cholestatic liver diseases. The company's lead asset, maralixibat, is a Phase 3-ready investigational oral drug with an established safety profile and strong Phase 2 efficacy data in orphan pediatric indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Mirum is led by Frazier EIR Chris Peetz.
